ONCOSEM UK LIMITED

Executive Summary

Oncosem UK Limited, a micro-entity operating in the manufacture of medical instruments, shows early-stage financial fragility with net assets near zero and current liabilities exceeding current assets. While statutory compliance is up to date and there is evidence of asset growth, the company’s limited operational history and small scale represent elevated solvency and liquidity risks. Further due diligence on cash flow and business operations is recommended before investment consideration.

ONCOSEM UK LIMITED - Analysis Report

Company Number: 14413695

Analysis Date: 2025-07-29 12:43 UTC

1. Risk Rating: HIGH
   The company exhibits significant solvency and liquidity concerns with minimal net assets and current liabilities exceeding current assets. The financial scale is very small, indicating limited operational scope and potential cash flow challenges.

2. Key Concerns:

• Negative and minimal net assets: Net assets are only £23 as of 2024, up from negative £350 previously, indicating very thin equity and potentially unstable financial footing.
• Current liabilities exceed current assets: £48,562 in current liabilities against £45,760 in current assets suggests working capital deficits and liquidity risk.
• Limited operational history and scale: Incorporated in late 2022, with only one employee and minimal share capital (£20), the company likely lacks established revenue streams and operational stability.

3. Positive Indicators:

• No overdue filings: Both accounts and confirmation statement filings are current, demonstrating compliance with statutory requirements.
• Active trading status with a website: The company is active with an operational website and contact details, indicating ongoing business activity.
• Recent increase in current assets: Current assets increased significantly from £475 in 2023 to £45,760 in 2024, which could indicate some business growth or capital injection.

4. Due Diligence Notes:

• Examine detailed cash flow and creditor arrangements: The notes do not clarify the nature of current liabilities; understanding creditor terms and payment schedules is critical.
• Review business model and revenue generation: Given the micro entity status and minimal employees, investigate how the company generates income and its future viability.
• Assess director and shareholder influence: The PSC data shows two individuals with significant control; understanding their roles, commitment, and financial backing is important.
• Investigate potential related party transactions: Given the origin and control by individuals with Turkish nationality and UK residency, related party dealings may impact financials.